Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.

doi:10.1158/1078-0432.CCR-20-1037

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2020

Ortiz-Cuaran Sandra, Mezquita Laura, Swalduz Aurélie, Aldea Mihalea, Mazieres Julien, Leonce Camille, Jovelet Cecile, Pradines Anne, Avrillon Virginie, Chumbi Flores Washington R, Lacroix Ludovic, Loriot Yohann, Westeel Virginie, Ngo-Camus Maud, Tissot Claire, Raynaud Christine, Gervais Radj, Brain Etienne, Monnet Isabelle, Giroux Leprieur Etienne, Caramella Caroline, Mahier-Aït Oukhatar Celine, Hoog-Labouret Natalie, de Kievit Frank, Howarth Karen, Morris Clive, Green Emma, Friboulet Luc, Chabaud Sylvie, Guichou Jean-François, Perol Maurice, Besse Benjamin, Blay Jean-Yves, Saintigny Pierre, Planchard David

Abstract excerpt

PURPOSE: The limited knowledge on the molecular profile of patients with BRAF-mutant non-small cell lung cancer (NSCLC) who progress under BRAF-targeted therapies (BRAF-TT) has hampered the development of subsequent therapeutic strategies for these patients. Here, we evaluated the clinical utility of circulating tumor DNA (ctDNA)-targeted sequencing to identify canonical BRAF mutations and genomic alterations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Circulating Tumor DNA

Share to Drug Resistance, Neoplasm

Share to Follow-Up Studies

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 32859654
DOI: 10.1158/1078-0432.CCR-20-1037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.PMID 32859654Read ↗

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.Semantic proximity Read ↗

Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.Semantic proximity Read ↗

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumorsSemantic proximity Read ↗

The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patientsSemantic proximity Read ↗

Genomic Insights into Innate Resistance in Early-Stage EGFR-Mutant Non-Small Cell Lung Cancer: A Comprehensive Analysis of Next-Generation Sequencing Data.Semantic proximity Read ↗

Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancerSemantic proximity Read ↗

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.Semantic proximity Read ↗

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.Semantic proximity Read ↗

Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patientsSemantic proximity Read ↗

BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscapeSemantic proximity Read ↗

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.